Servier shared a post on X:
“Precision medicine is changing how we treat patients, shifting from one-size-fits-all care to therapies tailored to each person’s biology. First applied in cancer, it now spans many diseases.
Targeted therapies like gene and RNA-based treatments offer new hope, especially for rare or complex diseases.
25% of FDA-approved drugs are precision meds, and 70% of oncology drugs in development follow this approach.
To reach its full potential, precision medicine needs better testing, reimagined trials and strong collaboration.
At Servier, we’re investing in the future of care.
More posts featuring Precision medicine.
